Evidence map›Paper›PMID 42360035›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Light-Controlled Modulation of 15-Lipoxygenase-1 Regulates Intestinal Inflammatory Signaling.

Anastasia Louka, Eirini-Eleni Kalaitzaki, Athanasios Panousis, Sotirios Bonoras, Charalampos Livas, George Froudakis, Ioannis Drygiannakis, Athina Damianaki, George Kolios, Vassilis Valatas and 1 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anastasia LoukaDepartment of Chemistry, University of Crete, Heraklion, Greece.
Eirini-Eleni KalaitzakiDepartment of Chemistry, University of Crete, Heraklion, Greece.
Athanasios PanousisDepartment of Chemistry, University of Crete, Heraklion, Greece.
Sotirios BonorasDepartment of Chemistry, University of Crete, Heraklion, Greece.
Charalampos LivasDepartment of Chemistry, University of Crete, Heraklion, Greece.
George FroudakisDepartment of Chemistry, University of Crete, Heraklion, Greece.
Ioannis DrygiannakisSchool of Medicine, University of Crete, Heraklion, Greece.ORCID 0000-0001-5845-2040
Athina DamianakiDepartment of Gastroenterology, University Hospital, Heraklion, Greece.
George KoliosDepartment of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.ORCID 0000-0002-2066-4782
Vassilis ValatasSchool of Medicine, University of Crete, Heraklion, Greece.ORCID 0000-0001-6660-0621
Nikolaos EleftheriadisDepartment of Chemistry, University of Crete, Heraklion, Greece.ORCID 0000-0002-1738-6419

Funding

European Union-NextGenerationEU TAEDR-0535850Hellenic Foundation for Research and Innovation 15511Hellenic Group for the Study of Inflammatory Bowel Diseases 2025EOMIFNEp3National Recovery and Resilience Plan Greece 2.0
6 · The paper itself

Abstract

Photopharmacology offers powerful opportunities for the spatiotemporal control of biological processes, yet the rational design of photoswitchable enzyme inhibitors remains challenging. Here, we report a target-guided strategy for the development of diazo-based photoswitchable inhibitors of human 15-lipoxygenase-1 (15-LOX-1), a key enzyme in inflammatory signaling, ferroptosis, and cancer. Guided by the structural features of known ligands, we developed three complementary photoswitch classes: reversible azobenzenes (ABs), azo-heteroarenes (HAs), and covalent azo-bis-alkynes (BAs). These compounds exhibit efficient E/Z photoisomerization and high bistability, supported by single-crystal x-ray diffraction and density functional theory calculations. Enzymatic inhibitory and kinetic studies revealed distinct activity and selectivity profiles within the tested substrates/isoenzyme: AB and HA derivatives function as E-ON/Z-OFF inhibitors, whereas BA derivatives display Z-ON/E-OFF behavior, enabling programmable light-controlled modulation. We validated 15-LOX-1 as a therapeutic target in cellular and in vivo mouse models of colonic inflammation, where inhibition suppressed IL-8 expression. Finally, using our reversible and covalent photoswitches, we demonstrate photoisomer-dependent suppression of IL-8. Beyond 15-LOX-1, this work establishes a generalizable framework for the rational development of selective photoswitchable inhibitors with tunable biological outcomes.

Indexed as

Arachidonate 15-LipoxygenaseAzo CompoundsInflammationIntestinesLightLipoxygenase InhibitorsAnimalsHumansMiceSignal TransductionALOX15 protein, humanArachidonate 15-LipoxygenaseAzo CompoundsLipoxygenase Inhibitors15‐lipoxygenase‐1azobenzenesintestinal inflammationphotopharmacologyphotoswitches

Identifiers

PMID42360035
PMCPMC13528541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.